May 15, 2025 04:52 AM EDTUpdated 06:30 AM

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Kyle LaHucik

Senior Reporter

Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Pathos AI col­lects $365M to fu­el 'bul­let­proof' on­col­o­gy tri­als and in-li­cense more can­cer drugs

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says